Spark Investment Management LLC lowered its position in ChemoCentryx, Inc. (NASDAQ:CCXI) by 12.6% during the second quarter, Holdings Channel reports. The firm owned 126,100 shares of the biopharmaceutical company’s stock after selling 18,200 shares during the period. Spark Investment Management LLC’s holdings in ChemoCentryx were worth $1,180,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of ChemoCentryx by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock valued at $8,727,000 after buying an additional 47,475 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of ChemoCentryx by 3.7% in the second quarter. Acadian Asset Management LLC now owns 885,442 shares of the biopharmaceutical company’s stock valued at $8,287,000 after buying an additional 31,724 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of ChemoCentryx by 31.0% in the first quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock valued at $4,489,000 after buying an additional 146,000 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of ChemoCentryx by 4.6% in the first quarter. Geode Capital Management LLC now owns 196,708 shares of the biopharmaceutical company’s stock valued at $1,432,000 after buying an additional 8,697 shares in the last quarter. Finally, P.A.W. Capital Corp boosted its position in shares of ChemoCentryx by 33.3% in the first quarter. P.A.W. Capital Corp now owns 160,000 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 40,000 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

ChemoCentryx, Inc. (CCXI) opened at 7.85 on Thursday. The company’s 50-day moving average price is $9.63 and its 200 day moving average price is $7.72. The stock’s market capitalization is $378.16 million. ChemoCentryx, Inc. has a 12 month low of $3.95 and a 12 month high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.14. The company had revenue of $8.23 million for the quarter. On average, analysts forecast that ChemoCentryx, Inc. will post ($0.69) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Spark Investment Management LLC Cuts Stake in ChemoCentryx, Inc. (CCXI)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/spark-investment-management-llc-cuts-stake-in-chemocentryx-inc-ccxi/1468051.html.

Several research analysts recently weighed in on CCXI shares. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, July 17th. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a research report on Tuesday.

In other ChemoCentryx news, insider Petrus Bekker sold 76,013 shares of the stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $9.95, for a total transaction of $756,329.35. Following the completion of the sale, the insider now directly owns 65,963 shares of the company’s stock, valued at approximately $656,331.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 223,649 shares of company stock valued at $2,157,360 over the last ninety days. 26.80% of the stock is owned by insiders.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.